Low-dose CT screening may benefit individuals at increased risk for lung cancer

May 20, 2012

Peter B. Bach, M.D., of the Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a systematic review to examine the evidence regarding the benefits and harms of low-dose computerized tomography (LDCT) screening for lung cancer, which is the leading cause of cancer death. "Most patients are diagnosed with advanced disease, resulting in a very low 5-year survival rate," the authors write. "Renewed enthusiasm for lung screening arose with the advent of LDCT imaging, which is able to identify smaller nodules than can chest radiographs."

For the review, the researchers identified 8 and 13 cohort studies of LDCT screening that met criteria for inclusion. Three randomized studies provided evidence on the effect of LDCT screening on mortality, of which the National Lung Screening Trial was the most informative, demonstrating that among 53,454 participants enrolled, screening resulted in significantly fewer lung cancer deaths (20 percent lower relative risk). The other 2 smaller studies showed no such benefit. "In terms of potential harms of LDCT screening, across all trials and cohorts, approximately 20 percent of individuals in each round of screening had positive results requiring some degree of follow-up, while approximately 1 percent had lung cancer. There was marked heterogeneity in this finding and in the frequency of follow-up investigations, biopsies, and percentage of surgical procedures performed in patients with ." The authors write that "Low-dose computed tomography screening may benefit individuals at an increased risk for lung cancer, but uncertainty exists about the potential harms of screening and the generalizability of results."

This report, a multisociety collaborative initiative, forms the basis of the and the American Society of Clinical Oncology , which, in summary is:

Recommendation 1: For smokers and former smokers ages 55 to 74 years who have smoked for 30 pack-years (number of packs of cigarettes smoked per day by the number of years the person has smoked) or more and either continue to smoke or have quit within the past 15 years, it is suggested that annual screening with LDCT should be offered over both annual screening with chest radiograph or no screening, but only in settings that can deliver the comprehensive care provided to National Lung Screening Trial participants. (Grade of evidence 2B, indicating a "weak recommendation based on moderate quality research data")

Recommendation 2: For individuals who have accumulated fewer than 30 pack-years of smoking or are either younger than 55 years or older than 74 years, or individuals who quit smoking more than 15 years ago, and for individuals with severe comorbidities that would preclude potentially curative treatment, limit life expectancy, or both, it is suggested that CT should not be performed. (Grade of evidence 2C, indicating a "weak recommendation based on low quality research data")

Explore further: Study finds that annual screening with chest x-ray does not reduce rate of lung cancer deaths

More information: JAMA, doi:10.1001/JAMA. 2012.5521

Related Stories

Asymptomatic often sent for lung cancer screening tests

March 13, 2012

(HealthDay) -- A majority of primary care physicians report ordering lung cancer screening tests for asymptomatic patients, according to research published in the March/April issue of the Annals of Family Medicine.

Recommended for you

Research holds promise for personalized lung cancer treatments

January 12, 2017

New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another. Scientists also identified ...

Tumor-seeking salmonella treats brain tumors

January 11, 2017

Biomedical engineers at Duke University have recruited an unlikely ally in the fight against the deadliest form of brain cancer—a strain of salmonella that usually causes food poisoning.

New genes identified that regulate the spread of cancers

January 11, 2017

Research led by the Wellcome Trust Sanger Institute has discovered a new biological target for drugs to reduce the spread of tumours in cancer patients. Published in Nature today, the study with genetically modified mice ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.